Balance Sheet Cybin Inc.

Stocks

HELP

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-10 pm EDT			5-day change	1st Jan Change
6.870 ^USD	+3.62%		+10.10%	-16.01%

Jun. 29	Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
Jun. 25	Helus Pharma Closes $50 Million Underwritten Offering	MT

33592690c88df.7MRp93NshBpUztPx61zQxgiMQ-mNxhjlUb162sWkvqg.mqELuSQi6Es_-v6FuiyliGviOcT-h0u1B8Qf4ojG7dGZsSzPHTTdbhu8gg

Published financial data: CYBIN INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2022	2023	2024	2025	2026 (USD)
Revenues	-	-	-	-	-
Total Revenues	-	-	-	-	-
Cost of Goods Sold, Total	-	-	-	-	-
Gross Profit	-	-	-	-	-
Selling General & Admin Expenses, Total	28.22M	21.34M	32.59M	45.37M	45.14M
Stock-Based Compensation (IS)	18.03M	4.69M	13.89M	42.87M	10.86M
R&D Expenses	17.59M	25.49M	32.36M	54.91M	86.59M
Other Operating Expenses, Total	63.84M	51.52M	78.84M	143M	143M
Operating Income	-63.84M	-51.52M	-78.84M	-143M	-143M
Interest Expense, Total	-	-	-	-	-2.92M
Interest And Investment Income	241K	603K	619K	8.29M	5.1M
Net Interest Expenses	241K	603K	619K	8.29M	2.18M
Currency Exchange Gains (Loss)	-309K	4.03M	137K	21.75M	492K
Other Non Operating Income (Expenses)	-	-	-	-28K	22K
EBT, Excl. Unusual Items	-63.91M	-46.89M	-78.08M	-113M	-140M
Gain (Loss) On Sale Of Investments	-29K	-260K	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	7K
Other Unusual Items	-3.7M	-342K	-	-	-8.12M
EBT, Incl. Unusual Items	-67.63M	-47.49M	-78.08M	-113M	-148M
Earnings From Continuing Operations	-67.63M	-47.49M	-78.08M	-113M	-148M
Net Income to Company	-67.63M	-47.49M	-78.08M	-113M	-148M
Net Income - (IS)	-67.63M	-47.49M	-78.08M	-113M	-148M
Net Income to Common Incl Extra Items	-67.63M	-47.49M	-78.08M	-113M	-148M
Net Income to Common Excl. Extra Items	-67.63M	-47.49M	-78.08M	-113M	-148M
Per Share Items
Net EPS - Basic	-15.36	-9.73	-9.41	-5.59	-4.25
Basic EPS - Continuing Operations	-15.36	-9.73	-9.41	-5.59	-4.25
Basic Weighted Average Shares Outstanding	4.4M	4.88M	8.3M	20.22M	34.8M
Net EPS - Diluted	-15.36	-9.88	-9.5	-5.59	-4.25
Diluted EPS - Continuing Operations	-15.36	-9.88	-9.5	-5.59	-4.25
Diluted Weighted Average Shares Outstanding	4.4M	4.88M	8.3M	20.22M	34.8M
Normalized Basic EPS	-9.07	-6	-5.88	-3.5	-2.51
Normalized Diluted EPS	-9.07	-6	-5.88	-3.5	-2.51
Supplemental Items
EBITDA	-63.67M	-51.28M	-78.58M	-143M	-142M
EBITA	-63.84M	-51.5M	-78.8M	-143M	-143M
EBIT	-63.84M	-51.52M	-78.84M	-143M	-143M
Normalized Net Income	-39.94M	-29.3M	-48.8M	-70.71M	-87.43M
Interest on Long-Term Debt	-	-	8K	7K	-
Supplemental Operating Expense Items
Advertising Expense	-	-	-	-	-
Marketing Expenses	3.69M	1.54M	2.79M	-	-
Selling and Marketing Expenses	3.69M	1.54M	2.79M	-	-
General and Administrative Expenses	24.53M	19.81M	29.8M	45.37M	45.14M
Research And Development Expense From Footnotes	17.59M	25.49M	32.36M	54.91M	86.59M
Stock-Based Comp., Other (Total)	18.03M	4.69M	13.89M	42.87M	10.86M
Total Stock-Based Compensation	18.03M	4.69M	13.89M	42.87M	10.86M

Fiscal Period: March	2022	2023	2024	2025	2026 (USD)
Assets
Cash And Equivalents	53.64M	16.63M	209M	135M	157M
Total Cash And Short Term Investments	53.64M	16.63M	209M	135M	157M
Accounts Receivable, Total	-	-	-	-	-
Other Receivables	2.1M	3.05M	4.48M	5.88M	5.03M
Total Receivables	2.1M	3.05M	4.48M	5.88M	5.03M
Prepaid Expenses	1.27M	1.73M	2.89M	22.16M	22.24M
Other Current Assets, Total	1.34M	1.77M	2.18M	2.91M	-
Total Current Assets	58.36M	23.18M	219M	166M	185M
Gross Property Plant And Equipment	713K	903K	1.35M	988K	811K
Accumulated Depreciation	-222K	-453K	-807K	-847K	-616K
Net Property Plant And Equipment	491K	450K	547K	141K	195K
Long-term Investments	242K	-	-	-	-
Goodwill	22.89M	24.79M	47.48M	51.49M	36.22M
Other Intangibles, Total	2.08M	5.47M	35.46M	41.02M	30.22M
Total Assets	84.06M	53.9M	302M	259M	251M
Liabilities
Accounts Payable, Total	4.23M	5.66M	9.8M	21.42M	17.99M
Accrued Expenses, Total	1.04M	-	-	-	-
Current Portion of Leases	-	-	291K	-	-
Other Current Liabilities	2.65M	-	-	-	1.38M
Total Current Liabilities	7.91M	5.66M	10.1M	21.42M	19.38M
Other Non Current Liabilities	-	-	-	-	-
Total Liabilities	7.91M	5.66M	10.1M	21.42M	19.38M
Common Stock, Total	141M	158M	444M	464M	492M
Additional Paid In Capital	525K	2.1M	11.75M	44.41M	34.97M
Retained Earnings	-101M	-148M	-226M	-339M	-390M
Comprehensive Income and Other	34.84M	36.12M	62.53M	67.79M	94.25M
Total Common Equity	76.16M	48.23M	292M	237M	232M
Total Equity	76.16M	48.23M	292M	237M	232M
Total Liabilities And Equity	84.06M	53.9M	302M	259M	251M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	4.64M	5.62M	20M	23.03M	61.98M
ECS Total Common Shares Outstanding	4.61M	5.28M	20M	21.61M	51.63M
Book Value / Share	16.52	9.13	14.59	10.98	4.49
Tangible Book Value	51.18M	17.97M	209M	145M	165M
Tangible Book Value Per Share	11.1	3.4	10.45	6.7	3.2
Total Debt	0	0	291K	0	0
Net Debt	-53.64M	-16.63M	-209M	-135M	-157M
Account Code - Inventory Valuation	5	5	5	6	3
Machinery, Total	713K	903K	930K	988K	811K
Full Time Employees	50	50	50	50	100

Fiscal Period: March	2022	2023	2024	2025	2026 (USD)
Net Income	-67.63M	-47.49M	-78.08M	-113M	-148M
Depreciation & Amortization - CF	168K	214K	363K	410K	88K
Amortization of Goodwill and Intangible Assets - (CF)	-	19K	37K	39K	28K
Depreciation & Amortization, Total	168K	233K	400K	449K	116K
Amortization of Deferred Charges, Total - (CF)	-	18K	24K	26K	4K
(Gain) Loss From Sale Of Asset	-	-	-	-	-7K
(Gain) Loss on Sale of Investments - (CF)	29K	260K	-	-	-
Asset Writedown & Restructuring Costs	-	-	18K	-	-
Stock-Based Compensation (CF)	18.03M	4.69M	13.89M	42.87M	10.86M
Other Operating Activities, Total	3.98M	-3.7M	-129K	-21.71M	5.01M
Change In Accounts Receivable	-773K	-948K	-1.09M	-1.41M	-934K
Change In Inventories	-	-	-	-	-
Change In Accounts Payable	2.47M	401K	-2.54M	11.61M	4.48M
Change in Other Net Operating Assets	-1.48M	-890K	-1.39M	-20M	-4.8M
Cash from Operations	-45.21M	-47.43M	-68.91M	-101M	-133M
Capital Expenditure	-105K	-142K	-21K	-35K	-188K
Sale of Property, Plant, and Equipment	-	-	-	-	10K
Cash Acquisitions	-	-	7.63M	-	-
Sale (Purchase) of Intangible assets	-415K	-3.17M	-689K	-1.93M	-1.18M
Investment in Marketable and Equity Securities, Total	-250K	-	-	-	-
Cash from Investing	-770K	-3.31M	6.92M	-1.97M	-1.36M
Long-Term Debt Issued, Total	-	-	-	-	44.5M
Total Debt Issued	-	-	-	-	44.5M
Long-Term Debt Repaid, Total	-	-	-149K	-290K	-20.15M
Total Debt Repaid	-	-	-149K	-290K	-20.15M
Issuance of Common Stock	38.77M	14.51M	271M	21.92M	156M
Repurchase of Common Stock	-	-	-	-	-75K
Other Financing Activities, Total	-2.99M	-950K	-16.68M	-1.44M	18.42M
Cash from Financing	35.78M	13.56M	255M	20.2M	198M
Foreign Exchange Rate Adjustments	-185K	168K	-162K	9.1M	-269K
Net Change in Cash	-10.38M	-37.01M	192M	-73.97M	63.34M
Supplemental Items
Cash Interest Paid	-	-	-	-	5.5M
Levered Free Cash Flow	-21.47M	-34.65M	-34.52M	-57.88M	-82.59M
Unlevered Free Cash Flow	-21.47M	-34.65M	-34.52M	-57.88M	-80.76M
Change In Net Working Capital	-752K	4.08M	-1.15M	9.79M	1.26M
Net Debt Issued / Repaid	-	-	-149K	-290K	24.35M

Fiscal Period: March	2022	2023	2024	2025	2026 (USD)
Profitability
Return on Assets	-45.29	-46.68	-27.69	-31.92	-41.35
Return on Total Capital	-49.17	-51.77	-28.95	-33.8	-44.92
Return On Equity %	-83.35	-76.36	-45.91	-42.76	-74.6
Return on Common Equity	-83.35	-76.36	-45.91	-42.76	-74.6
Margin Analysis
Gross Profit Margin %	-	-	-	-	-
SG&A Margin	-	-	-	-	-
EBITDA Margin %	-	-	-	-	-
EBITA Margin %	-	-	-	-	-
EBIT Margin %	-	-	-	-	-
Income From Continuing Operations Margin %	-	-	-	-	-
Net Income Margin %	-	-	-	-	-
Net Avail. For Common Margin %	-	-	-	-	-
Normalized Net Income Margin	-	-	-	-	-
Levered Free Cash Flow Margin	-	-	-	-	-
Unlevered Free Cash Flow Margin	-	-	-	-	-
Asset Turnover
Asset Turnover	-	-	-	-	-
Receivables Turnover (Average Receivables)	-	-	-	-	-
Short Term Liquidity
Current Ratio	7.38	4.09	21.65	7.75	9.52
Quick Ratio	7.05	3.48	21.14	6.58	8.38
Operating Cash Flow to Current Liabilities	-5.72	-8.38	-6.83	-4.73	-6.88
Days Sales Outstanding (Average Receivables)	-	-	-	-	-
Average Days Payable Outstanding	-	-	-	-	-
Long Term Solvency
Total Debt/Equity	-	-	0.1	-	-
Total Debt / Total Capital	-	-	0.1	-	-
Total Liabilities / Total Assets	9.41	10.51	3.34	8.28	7.71
EBIT / Interest Expense	-	-	-	-	-48.88
EBITDA / Interest Expense	-	-	-	-	-48.84
(EBITDA - Capex) / Interest Expense	-	-	-	-	-48.91
Total Debt / EBITDA	-	-	-0	-	-
Net Debt / EBITDA	0.84	0.32	2.66	0.95	1.1
Total Debt / (EBITDA - Capex)	-	-	-0	-	-
Net Debt / (EBITDA - Capex)	0.84	0.32	2.66	0.95	1.1
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	105.48	-19.45	53.21	81.91	38.6
EBITA, 1 Yr. Growth %	105.7	-19.33	53.01	81.61	38.28
EBIT, 1 Yr. Growth %	105.7	-19.3	53.03	81.58	38.27
Earnings From Cont. Operations, 1 Yr. Growth %	109.9	-29.78	64.41	44.9	81.35
Net Income, 1 Yr. Growth %	109.9	-29.78	64.41	44.9	81.35
Normalized Net Income, 1 Yr. Growth %	103.23	-26.63	66.52	44.9	71.42
Diluted EPS Before Extra, 1 Yr. Growth %	25.49	-35.69	-3.85	-40.55	5.26
Accounts Receivable, 1 Yr. Growth %	-	-	-	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	-11.85	-8.35	21.56	-74.22	98.98
Total Assets, 1 Yr. Growth %	-8.74	-35.88	460.37	-14.37	39.62
Tangible Book Value, 1 Yr. Growth %	-16.16	-64.88	1.06K	-30.76	64.27
Common Equity, 1 Yr. Growth %	-11.57	-36.66	505.23	-18.75	40.48
Cash From Operations, 1 Yr. Growth %	137.59	4.92	45.28	47.01	84.26
Capital Expenditures, 1 Yr. Growth %	-22.22	35.24	-85.21	66.67	623.08
Levered Free Cash Flow, 1 Yr. Growth %	274.4	61.41	-0.38	67.66	101.28
Unlevered Free Cash Flow, 1 Yr. Growth %	274.81	61.41	-0.38	67.66	96.84
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	-	28.65	11.09	66.95	59.09
EBITA, 2 Yr. CAGR %	471.64	28.82	11.1	66.7	58.91
EBIT, 2 Yr. CAGR %	471.64	28.84	11.13	66.69	58.89
Earnings From Cont. Operations, 2 Yr. CAGR %	489.83	21.41	7.45	54.35	62.66
Net Income, 2 Yr. CAGR %	489.83	21.41	7.45	54.35	62.66
Normalized Net Income, 2 Yr. CAGR %	473.35	22.11	10.53	55.34	58.14
Diluted EPS Before Extra, 2 Yr. CAGR %	190.21	-10.16	-21.36	-24.74	-20.58
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-10.12	5.55	-44.02	-29.46
Total Assets, 2 Yr. CAGR %	600.93	-23.51	89.55	119.05	7.74
Tangible Book Value, 2 Yr. CAGR %	494.52	-45.74	102.07	183.75	5.09
Common Equity, 2 Yr. CAGR %	625.21	-25.16	95.79	121.76	5.28
Cash From Operations, 2 Yr. CAGR %	471.36	57.89	23.46	46.14	64.31
Capital Expenditures, 2 Yr. CAGR %	-	2.56	-55.28	-50.35	253.51
Levered Free Cash Flow, 2 Yr. CAGR %	-	145.83	26.81	29.24	82.74
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	145.97	26.81	29.24	80.71
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-	-	36.37	30.94	57.11
EBITA, 3 Yr. CAGR %	-	197.61	36.42	30.88	56.92
EBIT, 3 Yr. CAGR %	-	197.65	36.44	30.89	56.91
Earnings From Cont. Operations, 3 Yr. CAGR %	-	190.16	34.32	18.71	63.24
Net Income, 3 Yr. CAGR %	-	190.16	34.32	18.71	63.24
Normalized Net Income, 3 Yr. CAGR %	-	188.93	35.41	20.97	60.89
Diluted EPS Before Extra, 3 Yr. CAGR %	-	75.62	-8.11	-28.58	-15.62
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	-0.6	-34.02	-15.43
Total Assets, 3 Yr. CAGR %	-	215.82	48.56	45.44	86.67
Tangible Book Value, 3 Yr. CAGR %	-	131.53	50.71	41.4	134.18
Common Equity, 3 Yr. CAGR %	-	221.76	50.22	46.04	88.59
Cash From Operations, 3 Yr. CAGR %	-	224.76	53.57	30.86	57.7
Capital Expenditures, 3 Yr. CAGR %	-	-	-46.22	-30.66	22.72
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	81.92	39.18	49.28
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	81.99	39.18	48.17
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-	-	-	-	45.04
EBITA, 5 Yr. CAGR %	-	-	-	136.03	45.01
EBIT, 5 Yr. CAGR %	-	-	-	136.04	45.02
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	125.41	45.01
Net Income, 5 Yr. CAGR %	-	-	-	125.41	45.01
Normalized Net Income, 5 Yr. CAGR %	-	-	-	125.41	44.08
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	25.13	-13.48
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	-	-	-13.34
Total Assets, 5 Yr. CAGR %	-	-	-	172.82	30.65
Tangible Book Value, 5 Yr. CAGR %	-	-	-	151.15	30.47
Common Equity, 5 Yr. CAGR %	-	-	-	177.25	30.31
Cash From Operations, 5 Yr. CAGR %	-	-	-	135.96	57.78
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-	14.22
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	82.25
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	81.47